Contact
searchSearch
HMP Global

FDA Alerts

FDA Alerts
FDA Approves Icotyde (icotrokinra) for the Treatment of Moderate-To-Severe Plaque Psoriasis in Adults and Pediatric Patients
03/18/2026
Jessica Garlewicz
The US Food and Drug Administration approved Icotyde (icotrokinra) for the treatment of moderate-to-severe plaque psoriasis in adults and pediatric patients aged 12 years and older.
The US Food and Drug Administration approved Icotyde (icotrokinra) for the treatment of moderate-to-severe plaque psoriasis in adults and pediatric patients aged 12 years and older.
The US Food and Drug...
03/18/2026
The Dermatologist
FDA Alerts
FDA Approves Cosentyx for the Treatment of Pediatric Patients Aged 12 Years and Older With Moderate-To-Severe Hidradenitis Suppurativa
03/17/2026
Jessica Garlewicz
The US Food and Drug Administration approved Cosentyx for the treatment of pediatric patients aged 12 years and older with moderate-to-severe hidradenitis suppurativa.
The US Food and Drug Administration approved Cosentyx for the treatment of pediatric patients aged 12 years and older with moderate-to-severe hidradenitis suppurativa.
The US Food and Drug...
03/17/2026
The Dermatologist
FDA Alerts
FDA Approves Sotyktu for the Treatment of Adults with Active Psoriatic Arthritis
03/10/2026
Jessica Garlewicz
On March 6, 2026, the US Food and Drug Administration approved Sotyktu (deucravacitinib) for the treatment of adults with active psoriatic arthritis.
On March 6, 2026, the US Food and Drug Administration approved Sotyktu (deucravacitinib) for the treatment of adults with active psoriatic arthritis.
On March 6, 2026, the US Food...
03/10/2026
The Dermatologist
Atopic dermatitis
FDA Alerts
FDA Approves Roflumilast Cream 0.05% for Treatment of Atopic Dermatitis in Children Aged 2 to 5
10/06/2025
Riya Gandhi, MA
On October 6, 2025, the US FDA approved ZORYVE (roflumilast) cream 0.05% for the topical treatment of mild-to-moderate atopic dermatitis in pediatric patients aged 2 to 5 years.
On October 6, 2025, the US FDA approved ZORYVE (roflumilast) cream 0.05% for the topical treatment of mild-to-moderate atopic dermatitis in pediatric patients aged 2 to 5 years.
On October 6, 2025, the US FDA...
10/06/2025
The Dermatologist
AD
FDA Alerts
FDA Approves Opzelura for Atopic Dermatitis in Children Aged 2–11
09/18/2025
Riya Gandhi, MA
US FDA approved Opzelura (ruxolitinib) cream 1.5% for the short-term and noncontinuous chronic treatment of mild-to-moderate AD in nonimmunocompromised children aged 2 years and older.
US FDA approved Opzelura (ruxolitinib) cream 1.5% for the short-term and noncontinuous chronic treatment of mild-to-moderate AD in nonimmunocompromised children aged 2 years and older.
US FDA approved Opzelura...
09/18/2025
The Dermatologist
FDA Alerts
Anzupgo Available for Prescribing Today
09/08/2025
Coleen Stern, MA
FDA recently approved delgocitinib cream as the first and only treatment indicated for moderate-to-severe chronic hand eczema in adults.
FDA recently approved delgocitinib cream as the first and only treatment indicated for moderate-to-severe chronic hand eczema in adults.
FDA recently approved...
09/08/2025
The Dermatologist
aging
FDA Alerts
FDA Approves Dupilumab as First Targeted Treatment for Bullous Pemphigoid in Adults
06/20/2025
Riya Gandhi, MA
FDA clears Dupixent for adults with bullous pemphigoid, offering steroid-sparing relief from painful blisters and relentless itch.
FDA clears Dupixent for adults with bullous pemphigoid, offering steroid-sparing relief from painful blisters and relentless itch.
FDA clears Dupixent for adults...
06/20/2025
The Dermatologist
psoriasis
FDA Alerts
FDA Approves Roflumilast Topical Foam 0.3% for Scalp and Body Plaque Psoriasis in Adults and Adolescents
05/22/2025
Riya Gandhi, MA
Arcutis’ once-daily steroid-free roflumilast foam offers effective, rapid itch relief and full-body clearance for patients 12 and older—expanding treatment options for hard-to-treat psoriasis sites.
Arcutis’ once-daily steroid-free roflumilast foam offers effective, rapid itch relief and full-body clearance for patients 12 and older—expanding treatment options for hard-to-treat psoriasis sites.
Arcutis’ once-daily steroid-free...
05/22/2025
The Dermatologist
Atopic dermatitis
FDA Alerts
FDA Approves Dupilumab (Dupixent) for Chronic Spontaneous Urticaria in Patients Aged 12 and Older
04/22/2025
Jessica Garlewicz
The US Food and Drug Administration (FDA) approved dupilumab for the treatment of chronic spontaneous urticaria in adults and adolescents aged 12 years and older.
The US Food and Drug Administration (FDA) approved dupilumab for the treatment of chronic spontaneous urticaria in adults and adolescents aged 12 years and older.
The US Food and Drug...
04/22/2025
The Dermatologist
Atopic dermatitis
FDA Alerts
FDA Approves Tapinarof Cream 1% for Atopic Dermatitis in Adults and Children
12/16/2024
Riya Gandhi, MA
Organon’s VTAMA cream, 1%, offers a steroid-free solution for patients 2 years and older with moderate-to-severe atopic dermatitis, featuring powerful skin clearance and rapid itch relief.
Organon’s VTAMA cream, 1%, offers a steroid-free solution for patients 2 years and older with moderate-to-severe atopic dermatitis, featuring powerful skin clearance and rapid itch relief.
Organon’s VTAMA cream, 1%,...
12/16/2024
The Dermatologist

Popular Articles

Saakshi-Khattri
Videos
Recap: Dual Diagnosing and Managing Psoriasis and Psoriatic Arthritis
04/16/2024
Saakshi Khattri, MD, FACR, FAAD
Explore Dr Khattri's take on the complexities in diagnosing and treating psoriasis and psoriatic arthritis, emphasizing the need for collaborative decision-making between dermatologists and rheumatologists for optimal patient outcomes.
Explore Dr Khattri's take on the complexities in diagnosing and treating psoriasis and psoriatic arthritis, emphasizing the need for collaborative decision-making between dermatologists and rheumatologists for optimal patient outcomes.
Explore Dr Khattri's take on the...
04/16/2024
The Dermatologist
Dr Patel
Videos
Advances in High-Risk Cutaneous Squamous Cell Carcinoma
05/07/2024
Vishal K. Patel, MD
In this interview, Dr Vishal Patel discusses recent advances in high-risk cutaneous squamous cell carcinoma, focusing on gene expression profiling and promising treatment approaches.
In this interview, Dr Vishal Patel discusses recent advances in high-risk cutaneous squamous cell carcinoma, focusing on gene expression profiling and promising treatment approaches.
In this interview, Dr Vishal...
05/07/2024
The Dermatologist
Derm Dx
What Caused This Forearm Nodule?
06/07/2024
Philip R. Cohen, MD
A 48-year-old man presented with a progressively enlarging tumor on his right wrist.
A 48-year-old man presented with a progressively enlarging tumor on his right wrist.
A 48-year-old man presented with...
06/07/2024
The Dermatologist
psoriasis
News
Overlap Phenotype Between Psoriasis and Atopic Dermatitis
07/18/2024
Jessica Garlewicz
Researchers compared the gene expression profiles of lesional and non-lesional skin biopsy tissues and the proteomic profiles of blood samples.
Researchers compared the gene expression profiles of lesional and non-lesional skin biopsy tissues and the proteomic profiles of blood samples.
Researchers compared the gene...
07/18/2024
The Dermatologist
Clinical Tips
Individualizing Botulinum Toxin Dosage
09/06/2024
Benjamin Barankin, MD, FRCPC
Keep these tips and pearls from dermatologic experts in mind for your next appointment.
Keep these tips and pearls from dermatologic experts in mind for your next appointment.
Keep these tips and pearls from...
09/06/2024
The Dermatologist
cover March 2026

Current Issue

March 2026
Volume 34
Issue 2
Current Issue
Issue Archive

Latest Quizzes and Trivia

Quiz
Disease Heterogeneity in PN
03/15/2026
Riya Gandhi, MA
Challenge your understanding of direct and indirect cytokine–nerve interactions and mechanical hypersensitivity of type 2 signaling in prurigo nodularis.
Challenge your understanding of direct and indirect cytokine–nerve interactions and mechanical hypersensitivity of type 2 signaling in prurigo nodularis.
Challenge your understanding of...
03/15/2026
The Dermatologist
Quiz
Rethinking Severity and JAK Inhibitor Strategy in Alopecia Areata
03/12/2026
Riya Gandhi, MA
How should clinicians redefine severe alopecia areata? When is it appropriate to treat ≤20% scalp involvement with oral JAK inhibitors? This expert-level quiz explores remission durability, treatment withdrawal, and practical strategies for...
How should clinicians redefine severe alopecia areata? When is it appropriate to treat ≤20% scalp involvement with oral JAK inhibitors? This expert-level quiz explores remission durability, treatment withdrawal, and practical strategies for...
How should clinicians redefine...
03/12/2026
The Dermatologist
Quiz
Cytokine Hierarchy and Sustained Pruritus in PN
03/10/2026
Riya Gandhi, MA
Explore the hierarchical and cooperative roles of IL-4, IL-13, and IL-31 in sustaining chronic itch and inflammation in prurigo nodularis.
Explore the hierarchical and cooperative roles of IL-4, IL-13, and IL-31 in sustaining chronic itch and inflammation in prurigo nodularis.
Explore the hierarchical and...
03/10/2026
The Dermatologist
Quiz
Type 2 Inflammation as a Pathogenic Driver in Prurigo Nodularis
03/05/2026
Riya Gandhi, MA
Test your understanding of how type 2 immune signaling drives chronic itch in prurigo nodularis through complex neuroimmune interactions.
Test your understanding of how type 2 immune signaling drives chronic itch in prurigo nodularis through complex neuroimmune interactions.
Test your understanding of how...
03/05/2026
The Dermatologist
psoriasis
Quiz
Distinguishing Feature of Generalized Pustular Psoriasis
03/02/2026
Jessica Garlewicz
What is a key distinguishing feature of generalized pustular psoriasis that differentiates it from plaque psoriasis?
What is a key distinguishing feature of generalized pustular psoriasis that differentiates it from plaque psoriasis?
What is a key distinguishing...
03/02/2026
The Dermatologist
psoriasis
Quiz
Quiz: Misdiagnosis of Generalized Pustular Psoriasis
03/02/2026
Jessica Garlewicz
What is the reason generalized pustular psoriasis is often misdiagnosed?
What is the reason generalized pustular psoriasis is often misdiagnosed?
What is the reason generalized...
03/02/2026
The Dermatologist
Quiz
Allergic Disease Progression: Genetics and Environment
02/26/2026
Riya Gandhi, MA
Explore the relationship between allergic disease trends, genetic timelines, and the clinical framework used to describe the progression of atopic conditions across childhood.
Explore the relationship between allergic disease trends, genetic timelines, and the clinical framework used to describe the progression of atopic conditions across childhood.
Explore the relationship between...
02/26/2026
The Dermatologist
Quiz
Early Intervention Strategies in Pediatric Atopic Dermatitis
02/26/2026
Riya Gandhi, MA
Assess your understanding of early skin barrier interventions in infants and the clinical rationale for prompt treatment of atopic dermatitis in young children, including implications for long-term disease outcomes.
Assess your understanding of early skin barrier interventions in infants and the clinical rationale for prompt treatment of atopic dermatitis in young children, including implications for long-term disease outcomes.
Assess your understanding of...
02/26/2026
The Dermatologist
Quiz
Air Pollution and Atopic Disease: Evaluating Epidemiologic Evidence
02/26/2026
Riya Gandhi, MA
Test your knowledge of the epidemiologic data examining environmental exposures and their association with atopic disease development. This quiz explores key population-level observations shaping modern allergy research.
Test your knowledge of the epidemiologic data examining environmental exposures and their association with atopic disease development. This quiz explores key population-level observations shaping modern allergy research.
Test your knowledge of the...
02/26/2026
The Dermatologist
Quiz
Clinical Trial Evaluation of Eyebrow and Eyelash Regrowth in AA
02/05/2026
Riya Gandhi, MA
Test your understanding of how clinical trials assess and define success in eyebrow and eyelash regrowth for patients with alopecia areata.
Test your understanding of how clinical trials assess and define success in eyebrow and eyelash regrowth for patients with alopecia areata.
Test your understanding of how...
02/05/2026
The Dermatologist

HMP Global Products

Events

HMP Education Logo
HMP Omnimedia Logo
HMP Europe Logo
© 2026 HMP Global. All Rights Reserved.
Cookie Policy Privacy Policy Terms of Use